Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
279 Leser
Artikel bewerten:
(2)

Galapagos NV: Publication of the annual report and invitation to the Annual and Extraordinary Shareholders' Meetings

Finanznachrichten News

Mechelen, Belgium; 25 March 2016 - Today Galapagos NV (Euronext & NASDAQ: GLPG) has published its Annual Report for the financial year 2015.

The Annual Report for the financial year 2015, including a review of figures and performance, is available online on http://reports.glpg.com/annual-report-2015/en/ and can also be downloaded as PDF.

Furthermore, Galapagos has the honor to invite its Shareholders, Warrant Holders, Directors and Statutory Auditor to its Annual and Extraordinary Shareholders' Meetings that will be held on Tuesday 26 April 2016 at 2:00 p.m. (CET) at the registered office of the Company.

In order to be admitted to the Shareholders' Meetings, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code and article 29 of the Company's articles of association, and fulfill the formalities described in the convening notices.  The convening notices and other documents pertaining to the Shareholders' Meetings can be consulted on our website.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.  Our pipeline comprises three Phase 2, three Phase 1, five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications.  We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world.  Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives.  The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  More information at www.glpg.com.

Contact
Galapagos NV

Investors:                                                      Media:
Elizabeth Goodwin                                             Evelyn Fox
VP IR & Corporate Communications                  Director Communications
+1 781 460 1784                                            +31 6 53 591 999
ir@glpg.com (mailto:ir@glpg.com)                                                     communications@glpg.com (mailto:communications@glpg.com)

Forward-Looking Statements
This release may contain forward-looking statements.  Galapagos cautions the reader that forward-looking statements are not guarantees of future performance.  Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements.  In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.  A list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on Form 20F filed with the SEC and other filings and reports filed by Galapagos with the SEC.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.


Publication of AR and invitation for AGM (http://hugin.info/133350/R/1997716/736508.pdf)



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

HUG#1997716
© 2016 GlobeNewswire (Europe)
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.